Cardinal Health (NYSE:CAH – Get Free Report) issued an update on its FY 2027 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 12.400-12.600 for the period, compared to the consensus EPS estimate of 12.050. The company issued revenue guidance of -.
Cardinal Health Price Performance
Cardinal Health stock opened at $240.08 on Wednesday. The business has a 50 day simple moving average of $228.37 and a 200-day simple moving average of $216.66. Cardinal Health has a 12 month low of $137.75 and a 12 month high of $258.30. The stock has a market capitalization of $56.23 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 1.16 and a beta of 0.49.
Cardinal Health (NYSE:CAH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.62% and a negative return on equity of 92.61%. The company had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. During the same quarter in the prior year, the firm earned $2.08 EPS. Cardinal Health’s quarterly revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, equities research analysts anticipate that Cardinal Health will post 10.77 EPS for the current year.
Cardinal Health Announces Dividend
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CAH. Wall Street Zen upgraded shares of Cardinal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Robert W. Baird set a $248.00 price objective on shares of Cardinal Health in a research note on Friday, May 1st. Mizuho lifted their target price on shares of Cardinal Health from $235.00 to $240.00 and gave the stock an “outperform” rating in a research note on Thursday, July 23rd. Bank of America increased their price target on Cardinal Health from $240.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Finally, Wells Fargo & Company decreased their price objective on Cardinal Health from $256.00 to $245.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Fifteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $252.87.
Read Our Latest Stock Report on CAH
Key Stories Impacting Cardinal Health
Here are the key news stories impacting Cardinal Health this week:
- Positive Sentiment: Profit and guidance beat expectations. Cardinal Health reported fiscal Q4 non-GAAP EPS of $2.91, up from $2.08 a year earlier and $0.49 above consensus. Fiscal 2027 adjusted EPS guidance of $12.40–$12.60 also exceeded the approximately $12.05 analyst estimate, implying 13%–15% growth. Cardinal Health forecasts full-year profit above estimates on specialty drug strength
- Positive Sentiment: Specialty-drug and medtech performance supported earnings. Sustained demand for specialty pharmaceuticals helped drive the outlook, while medical technology profits nearly doubled in the quarter. Cardinal also said it now exclusively serves nearly half of the cell-and-gene therapy market, strengthening its position in a higher-margin growth niche. Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
- Positive Sentiment: Large buyback authorization added support. The board approved an additional $5 billion for share repurchases after Cardinal bought back $1.4 billion of stock during fiscal 2026. The company also declared a quarterly dividend of $0.5158 per share, payable October 15. Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results
- Neutral Sentiment: Revenue growth was solid but missed forecasts. Fourth-quarter revenue rose 6% year over year to $63.67 billion, but fell short of the roughly $65.15 billion consensus estimate. Fiscal 2026 operating cash flow reached $5.2 billion and adjusted free cash flow was $5.0 billion. Cardinal Health shares rise as profit beats estimates and outlook tops forecasts
- Negative Sentiment: Some earnings quality and valuation concerns remain. About $0.31 of quarterly adjusted EPS came from a one-time IEEPA tariff refund, while the Global Medical Products and Distribution segment reported declining revenue. With CAH trading near its 52-week high and at an elevated valuation, investors may demand continued execution to justify further gains. Can Cardinal Health’s Strong Earnings Guidance Offset a Mixed Quarter?
Hedge Funds Weigh In On Cardinal Health
A number of large investors have recently modified their holdings of the company. University of Texas Texas AM Investment Management Co. acquired a new stake in Cardinal Health during the 4th quarter worth approximately $26,000. Jones Financial Companies Lllp grew its stake in Cardinal Health by 198.3% during the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock worth $27,000 after buying an additional 14,034 shares during the period. Bank of Jackson Hole Trust acquired a new stake in shares of Cardinal Health in the fourth quarter worth $27,000. Turning Point Benefit Group Inc. purchased a new position in shares of Cardinal Health in the 3rd quarter valued at $31,000. Finally, JPL Wealth Management LLC purchased a new position in shares of Cardinal Health in the 3rd quarter valued at $31,000. 87.17% of the stock is currently owned by hedge funds and other institutional investors.
About Cardinal Health
Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.
The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.
Featured Stories
- Five stocks we like better than Cardinal Health
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.
